Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Cancer Cell International
Published in: Cancer Cell International 1/2021

Open Access 01-12-2021 | Thyroid Cancer | Review

Epigenetic modification and BRAF gene mutation in thyroid carcinoma

Authors: Guo Huang, Juan Chen, Jun Zhou, Shuai Xiao, Weihong Zeng, Jiliang Xia, Xi Zeng

Published in: Cancer Cell International | Issue 1/2021

Login to get access

Abstract

Thyroid cancer remains the most prevailing endocrine malignancy, and a progressively increasing incidence rate has been observed in recent years, with 95% of thyroid cancer represented by differentiated thyroid carcinomas. The genetics and epigenetics of thyroid cancer are gradually increasing, and gene mutations and methylation changes play an important roles in its occurrence and development. Although the role of RAS and BRAF mutations in thyroid cancer have been partially clarified,but the pathogenesis and molecular mechanisms of thyroid cancer remain to be elucidated. Epigenetic modification refer to genetic modification that does not change the DNA sequence of a gene but causes heritable phenotypic changes in its expression. Epigenetic modification mainly includes four aspects: DNA methylation, chromatin remodelling, noncoding RNA regulation, and histone modification. This article reviews the importance of thyroid cancer epigenetic modification and BRAF gene mutation in the treatment of thyroid cancer.
Literature
1.
Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. CA Cancer J Clin. 2019;69:7–34.PubMed
2.
Miller KD, Nogueira L, et al. Cancer treatment and survivorship statistics, 2019.CA Cancer J Clin 2019; 69(5): 363–385.
3.
Wong R, Farrell SG, Grossmann M. Thyroid nodules: diagnosis and management. Med J Aust. 2018;209:92–8.PubMed
4.
Nagy R, Ringel MD. Genetic predisposition for nonmedullary thyroid cancer. Horm Cancer. 2015;6(1):13–20.PubMed
5.
Gogna S, Goldberg M, Samson D, et al. Medullary thyroid cancer in patients older than 45-epidemiologic trends and predictors of survival. Cancers (Basel). 2020;12(11):3124.
6.
Molinaro E, Romei C, Biagini A, et al. Anaplastic thyroid carcinoma: from clinicopathology to genetics and advanced therapies. Nat Rev Endocrinol. 2017;13(11):644–60.PubMed
7.
Baylin SB, Jones PA. A decade of exploring the cancer epigenome—biological and translational implications. Nat Rev Cancer. 2011;11(10):726–34.PubMedPubMedCentral
8.
9.
Guo LC, Zhu WD, Ma XY, et al. Mutations of genes including DNMT3A detected by next-generation sequencing in thyroid cancer. Cancer Biol Ther. 2019;20(3):240–6.PubMed
10.
He J, Zhou M, Li X, et al. SLC34A2 simultaneously promotes papillary thyroid carcinoma growth and invasion through distinct mechanisms. Oncogene. 2020;39(13):2658–75.PubMed
11.
Zhao X, Hu X. Downregulated long noncoding RNA LINC00313 inhibits the epithelial-mesenchymal transition, invasion, and migration of thyroid cancer cells through inhibiting the methylation of ALX4. J Cell Physiol. 2019;234(11):20992–1004.PubMed
12.
Li G, Tian Y, Zhu WG. The roles of histone deacetylases and their inhibitors in cancer therapy. Front Cell Dev Biol. 2020;8:576946.PubMedPubMedCentral
13.
Puppin C, Passon N, Lavarone E, et al. Levels of histone acetylation in thyroid tumors. Biochem Biophys Res Commun. 2011;411(4):679–83.PubMed
14.
15.
Xia F, Wang W, Jiang B, et al. DNA methylation-mediated silencing of miR-204 is a potential prognostic marker for papillary thyroid carcinoma. Cancer Manag Res. 2019;11:1249–62.PubMedPubMedCentral
16.
Peng X, Ji C, Tan L, et al. Long non-coding RNA TNRC6C-AS1 promotes methylation of STK4 to inhibit thyroid carcinoma cell apoptosis and autophagy via Hippo signalling pathway. J Cell Mol Med. 2020;24(1):304–16.PubMed
17.
Lan Q, Liu PY, Haase J, et al. The critical role of RNA m(6)A methylation in cancer. Cancer Res. 2019;79(7):1285–92.
18.
Wang K, Jiang L, Zhang Y, et al. Progression of thyroid carcinoma is promoted by the m6A methyltransferase METTL3 through regulating m(6)A methylation on TCF1. Onco Targets Ther. 2020;13:1605–12.PubMedPubMedCentral
19.
Torregrossa L, Viola D, Sensi E, et al. Papillary thyroid carcinoma with rare Exon 15 BRAF mutation has indolent behavior: a single-institution experience. J Clin Endocrinol Metab. 2016;101(11):4413–20.PubMed
20.
Lavoie H, Therrien M. Regulation of RAF protein kinases in ERK signalling. Nat Rev Mol Cell Biol. 2015;16(5):281–98.PubMed
21.
Xing M, Cohen Y, Mambo E, et al. Early occurrence of RASSF1A hypermethylation and its mutual exclusion with BRAF mutation in thyroid tumorigenesis. Cancer Res. 2004;64(5):1664–8.PubMed
22.
Grawenda AM, O’Neill E. Clinical utility of RASSF1A methylation in human malignancies. Br J Cancer. 2015;113(3):372–81.PubMedPubMedCentral
23.
Kunstman JW, Korah R, Healy JM, et al. Quantitative assessment of RASSF1A methylation as a putative molecular marker in papillary thyroid carcinoma. Surgery. 2013;154(6):1255–62.PubMed
24.
Niu H, Yang J, Yang K, et al. The relationship between RASSF1A promoter methylation and thyroid carcinoma: a meta-analysis of 14 articles and a bioinformatics of 2 databases (PRISMA). Medicine (Baltimore). 2017;96(46):e8630.
25.
Jiang JL, Tian GL, Chen SJ, et al. Promoter methylation of p16 and RASSF1A genes may contribute to the risk of papillary thyroid cancer: a meta-analysis. Exp Ther Med. 2015;10(4):1549–55.PubMedPubMedCentral
26.
Porra V, Ferraro-Peyret C, Durand C, et al. Silencing of the tumor suppressor gene SLC5A8 is associated with BRAF mutations in classical papillary thyroid carcinomas. J Clin Endocrinol Metab. 2005;90(5):3028–35.PubMed
27.
Fakhruddin N, Jabbour M, Novy M, et al. BRAF and NRAS mutations in papillary thyroid carcinoma and concordance in BRAF mutations between primary and corresponding lymph node metastases. Sci Rep. 2017;7(1):4666.PubMedPubMedCentral
28.
Khatami F, Larijani B, Heshmat R, et al. Hypermethylated RASSF1 and SLC5A8 promoters alongside BRAF(V600E) mutation as biomarkers for papillary thyroid carcinoma. J Cell Physiol. 2020;235(10):6954–68.PubMed
29.
Oishi N, Vuong HG, Mochizuki K, et al. Loss of 5-hydroxymethylcytosine is an epigenetic hallmark of thyroid carcinomas with TERT promoter mutations. Endocr Pathol. 2020;31(4):359–66.PubMed
30.
Bu R, Siraj AK, Divya SP, et al. Telomerase reverse transcriptase mutations are independent predictor of disease-free survival in Middle Eastern papillary thyroid cancer. Int J Cancer. 2018;142(10):2028–39.PubMed
31.
Liu R, Zhang T, Zhu G, et al. Regulation of mutant TERT by BRAF V600E/MAP kinase pathway through FOS/GABP in human cancer. Nat Commun. 2018;9(1):579.PubMedPubMedCentral
32.
Liu R, Bishop J, Zhu G, et al. Mortality risk stratification by combining BRAF V600E and TERT promoter mutations in papillary thyroid cancer: genetic duet of BRAF and TERT promoter mutations in thyroid cancer mortality. JAMA Oncol. 2017;3(2):202–8.PubMed
33.
34.
Pozdeyev N, Gay LM, Sokol ES, et al. Genetic analysis of 779 advanced differentiated and anaplastic thyroid cancers. Clin Cancer Res. 2018;24(13):3059–68.PubMedPubMedCentral
35.
Smekalova EM, Petrova OA, Zvereva MI, et al. Hansenula polymorpha TERT: a telomerase catalytic subunit isolated in recombinant form with limited reverse transcriptase activity. Acta Naturae. 2012;4(1):70–3.PubMedPubMedCentral
36.
Liu X, Bishop J, Shan Y, et al. Highly prevalent TERT promoter mutations in aggressive thyroid cancers. Endocr Relat Cancer. 2013;20(4):603–10.PubMedPubMedCentral
37.
Lee J, Ha EJ, Roh J, et al. Presence of TERT +/- BRAF V600E mutation is not a risk factor for the clinical management of patients with papillary thyroid microcarcinoma. Surgery. 2021;170(3):743–7.PubMed
38.
Yu PC, Tan LC, Zhu XL, et al. Arms-qPCR improves detection sensitivity of earlier diagnosis of papillary thyroid cancers with worse prognosis determined by coexisting BRAF V600E and Tert promoter mutations. Endocr Pract. 2021;27(7):698–705.PubMed
39.
McKelvey BA, Zeiger MA, Umbricht CB. Characterization of TERT and BRAF copy number variation in papillary thyroid carcinoma: an analysis of the cancer genome atlas study. Genes Chromosomes Cancer. 2021;60(6):403–9.PubMed
40.
Ylli D, Patel A, Jensen K, et al. Microfluidic droplet digital PCR Is a powerful tool for detection of BRAF and TERT mutations in papillary thyroid carcinomas. Cancers (Basel). 2019;11(12):1916.
41.
Liu J, Liu R, Shen X, et al. The genetic duet of BRAF V600E and TERT promoter mutations robustly predicts loss of radioiodine avidity in recurrent papillary thyroid cancer. J Nucl Med. 2020;61(2):177–82.PubMed
42.
Song YS, Yoo SK, Kim HH, et al. Interaction of BRAF-induced ETS factors with mutant TERT promoter in papillary thyroid cancer. Endocr Relat Cancer. 2019;26(6):629–41.PubMed
43.
Yang S, Leone DA, Biswas A, et al. Concordance of somatic mutation profiles (BRAF, NRAS, and TERT) and tumoral PD-L1 in matched primary cutaneous and metastatic melanoma samples. Hum Pathol. 2018;82:206–14.PubMed
44.
Pellegrini C, Di Nardo L, Cipolloni G, et al. Heterogeneity of BRAF, NRAS, and TERT promoter mutational status in multiple melanomas and association with MC1R genotype: findings from molecular and immunohistochemical analysis. J Mol Diagn. 2018;20(1):110–22.PubMed
45.
Sheen YS, Chu CY. Co-occurrence of TERT promotor mutations with BRAF or NRAS alterations correlates with worse prognosis in melanoma. Br J Dermatol. 2021;184(3):390–1.PubMed
46.
Nakajima N, Nobusawa S, Nakata S, et al. BRAF V600E, TERT promoter mutations and CDKN2A/B homozygous deletions are frequent in epithelioid glioblastomas: a histological and molecular analysis focusing on intratumoral heterogeneity. Brain Pathol. 2018;28(5):663–73.PubMed
47.
Gabler L, Lotsch D, Kirchhofer D, et al. TERT expression is susceptible to BRAF and ETS-factor inhibition in BRAF(V600E)/TERT promoter double-mutated glioma. Acta Neuropathol Commun. 2019;7(1):128.PubMedPubMedCentral
48.
Kim TH, Kim YE, Ahn S, et al. TERT promoter mutations and long-term survival in patients with thyroid cancer. Endocr Relat Cancer. 2016;23(10):813–23.PubMed
49.
Stephen JK, Chen KM, Merritt J, et al. Methylation markers differentiate thyroid cancer from benign nodules. J Endocrinol Invest. 2018;41(2):163–70.PubMed
50.
Gauchotte G, Lacomme S, Brochin L, et al. Retinoid acid receptor expression is helpful to distinguish between adenoma and well-differentiated carcinoma in the thyroid. Virchows Arch. 2013;462(6):619–32.PubMed
51.
Hoque MO, Rosenbaum E, Westra WH, et al. Quantitative assessment of promoter methylation profiles in thyroid neoplasms. J Clin Endocrinol Metab. 2005;90(7):4011–8.PubMed
52.
Huang XQ, Zhou ZQ, Zhang XF, et al. Overexpression of SMOC2 attenuates the tumorigenicity of hepatocellular carcinoma cells and is associated with a positive postoperative prognosis in human hepatocellular carcinoma. J Cancer. 2017;8(18):3812–27.PubMedPubMedCentral
53.
Lu H, Ju DD, Yang GD, et al. Targeting cancer stem cell signature gene SMOC-2 overcomes chemoresistance and inhibits cell proliferation of endometrial carcinoma. EBioMedicine. 2019;40:276–89.PubMed
54.
Kim HS, Choi JH, Lee JY, et al. Downregulation of SMOC2 expression in papillary thyroid carcinoma and its prognostic significance. Sci Rep. 2020;10(1):4853.PubMedPubMedCentral
55.
Zhou C, Li J, Wang Y, et al. Association of BRAF gene and TSHR with cervical lymph node metastasis of papillary thyroid microcarcinoma. Oncol Lett. 2019;17(1):183–94.PubMed
56.
Kartal K, Onder S, Kosemehmetoglu K, et al. Methylation status of TSHr in well-differentiated thyroid cancer by using cytologic material. BMC Cancer. 2015;15:824.PubMedPubMedCentral
57.
Khan MS, Pandith AA, Masoodi SR, et al. Epigenetic silencing of TSHR gene in thyroid cancer patients in relation to their BRAF V600E mutation status. Endocrine. 2014;47(2):449–55.PubMed
58.
Aliyev A, Gupta M, Nasr C, et al. Circulating thyroid-stimulating hormone receptor messenger rna as a marker of tumor aggressiveness in patients with papillary thyroid microcarcinoma. Endocr Pract. 2015;21(7):777–81.PubMed
59.
Moulana FI, Priyani A, de Silva M, et al. BRAF-oncogene-induced senescence and the role of thyroid-stimulating hormone signaling in the progression of papillary thyroid carcinoma. Horm Cancer. 2018;9(1):1–11.PubMed
60.
Hansen KD, Timp W, Bravo HC, et al. Increased methylation variation in epigenetic domains across cancer types. Nat Genet. 2011;43(8):768–75.PubMedPubMedCentral
61.
Aslani S, Mahmoudi M, Karami J, et al. Epigenetic alterations underlying autoimmune diseases. Autoimmunity. 2016;49(2):69–83.PubMed
62.
Uysal F, Cinar O, Can A. Knockdown of Dnmt1 and Dnmt3a gene expression disrupts preimplantation embryo development through global DNA methylation. J Assist Reprod Genet. 2021;116(3):e423.
63.
Siraj AK, Pratheeshkumar P, Parvathareddy SK, et al. Prognostic significance of DNMT3A alterations in Middle Eastern papillary thyroid carcinoma. Eur J Cancer. 2019;117:133–44.PubMed
64.
Xing X, Mu N, Yuan X, et al. PLEKHS1 over-expression is associated with metastases and poor outcomes in papillary thyroid carcinoma. Cancers (Basel). 2020;12(8):1–17.
65.
Jung CK, Jung SH, Jeon S, et al. Risk stratification using a novel genetic classifier including PLEKHS1 promoter mutations for differentiated thyroid cancer with distant metastasis. Thyroid. 2020;30(11):1589–600.PubMed
66.
Wei F, Wu Y, Wang Z, et al. Diagnostic significance of DNA methylation of PTEN and DAPK in thyroid tumors. Clin Endocrinol (Oxf). 2020;93(2):187–95.
67.
Hou P, Ji M, Xing M. Association of PTEN gene methylation with genetic alterations in the phosphatidylinositol 3-kinase/AKT signaling pathway in thyroid tumors. Cancer. 2008;113(9):2440–7.PubMed
68.
Khatami F, Larijani B, Heshmat R, et al. Meta-analysis of promoter methylation in eight tumor-suppressor genes and its association with the risk of thyroid cancer. PLoS ONE. 2017;12(9):e184892.
69.
Alvarez-Nunez F, Bussaglia E, Mauricio D, et al. PTEN promoter methylation in sporadic thyroid carcinomas. Thyroid. 2006;16(1):17–23.PubMed
70.
Frasca F, Vella V, Aloisi A, et al. p73 tumor-suppressor activity is impaired in human thyroid cancer. Cancer Res. 2003;63(18):5829–37.PubMed
71.
Tang Q, Zhao H, Yang B, et al. WIF-1 gene inhibition and Wnt signal transduction pathway activation in NSCLC tumorigenesis. Oncol Lett. 2017;13(3):1183–8.PubMedPubMedCentral
72.
Zhang Y, Tu Y, Zhao J, et al. Reversion-induced LIM interaction with Src reveals a novel Src inactivation cycle. J Cell Biol. 2009;184(6):785–92.PubMedPubMedCentral
73.
Botezatu A, Iancu IV, Plesa A, et al. Methylation of tumour suppressor genes associated with thyroid cancer. Cancer Biomark. 2019;25(1):53–65.PubMed
74.
Yin Y, Che K, Hu J, et al. Hypermethylation of the RSK4 promoter associated with BRAF V600E promotes papillary thyroid carcinoma. Int J Oncol. 2020;56(5):1284–93.PubMed
75.
Hu C, Dai J, Lin X, et al. Effect of RSK4 on biological characteristics of gastric cancer. Cancer Manag Res. 2020;12:611–9.PubMedPubMedCentral
76.
Ma J, Wang K, Chai J, et al. High RSK4 expression constitutes a predictor of poor prognosis for patients with clear cell renal carcinoma. Pathol Res Pract. 2021;227:153642.PubMed
77.
Chrysostomou S, Roy R, Prischi F, et al. Repurposed floxacins targeting RSK4 prevent chemoresistance and metastasis in lung and bladder cancer. Sci Transl Med. 2021;13(602):eaba4627.PubMed
78.
Lin JD, Fu SS, Chen JY, et al. Clinical manifestations and gene expression in patients with conventional papillary thyroid carcinoma carrying the BRAF(V600E) mutation and BRAF pseudogene. Thyroid. 2016;26(5):691–704.PubMed
79.
Myers AP, Corson LB, Rossant J, et al. Characterization of mouse Rsk4 as an inhibitor of fibroblast growth factor-RAS-extracellular signal-regulated kinase signaling. Mol Cell Biol. 2004;24(10):4255–66.PubMedPubMedCentral
80.
Lopez-Vicente L, Pons B, Coch L, et al. RSK4 inhibition results in bypass of stress-induced and oncogene-induced senescence. Carcinogenesis. 2011;32(4):470–6.PubMed
81.
Gomez SJ. Diagnostic and prognostic markers in differentiated thyroid cancer. Curr Genomics. 2011;12(8):597–608.
82.
Jin S, Borkhuu O, Bao W, et al. Signaling pathways in thyroid cancer and their therapeutic implications. J Clin Med Res. 2016;8(4):284–96.PubMedPubMedCentral
83.
White MG, Nagar S, Aschebrook-Kilfoy B, et al. Epigenetic alterations and canonical pathway disruption in papillary thyroid cancer: a genome-wide methylation analysis. Ann Surg Oncol. 2016;23(7):2302–9.PubMed
84.
Cabanillas ME, Dadu R, Iyer P, et al. Acquired secondary RAS mutation in BRAF(V600E)-mutated thyroid cancer patients treated with BRAF inhibitors. Thyroid. 2020;30(9):1288–96.PubMedPubMedCentral
85.
Piscazzi A, Costantino E, Maddalena F, et al. Activation of the RAS/RAF/ERK signaling pathway contributes to resistance to sunitinib in thyroid carcinoma cell lines. J Clin Endocrinol Metab. 2012;97(6):E898–906.PubMed
86.
Bonaldi E, Gargiuli C, De Cecco L, et al. BRAF inhibitors induce feedback activation of RAS pathway in thyroid cancer cells. Int J Mol Sci. 2021;22(11):5744.PubMedPubMedCentral
87.
Ahronian LG, Corcoran RB. Effective MAPK Inhibition is critical for therapeutic responses in colorectal cancer with BRAF mutations. Mol Cell Oncol. 2016;3(1):e1048405.PubMed
88.
Luckett KA, Cracchiolo JR, Krishnamoorthy GP, et al. Co-inhibition of SMAD and MAPK signaling enhances 124I uptake in BRAF-mutant thyroid cancers. Endocr Relat Cancer. 2021;28(6):391–402.PubMedPubMedCentral
89.
Hicks HM, McKenna LR, Espinoza VL, et al. Inhibition of BRAF and ERK1/2 has synergistic effects on thyroid cancer growth in vitro and in vivo. Mol Carcinog. 2021;60(3):201–12.PubMed
90.
Jimenez-Mora E, Gallego B, Diaz-Gago S, et al. BRAF inhibition induces cytoprotective autophagy through AMPK in thyroid cancer cells. Int J Mol Sci. 2021;22(11):6033.PubMedPubMedCentral
91.
Su X, Li P, Han B, et al. Vitamin C sensitizes BRAF(V600E) thyroid cancer to PLX4032 via inhibiting the feedback activation of MAPK/ERK signal by PLX4032. J Exp Clin Cancer Res. 2021;40(1):34.PubMedPubMedCentral
92.
Zou M, Baitei EY, Al-Rijjal RA, et al. KRAS(G12D)-mediated oncogenic transformation of thyroid follicular cells requires long-term TSH stimulation and is regulated by SPRY1. Lab Invest. 2015;95(11):1269–77.PubMedPubMedCentral
93.
Traversi F, Stooss A, Dettmer MS, et al. BRAF(V600E) overrides NOTCH signaling in thyroid cancer. Thyroid. 2021;31(5):787–99.PubMed
94.
Weinberger PM, Adam BL, Gourin CG, et al. Association of nuclear, cytoplasmic expression of galectin-3 with beta-catenin/Wnt-pathway activation in thyroid carcinoma. Arch Otolaryngol Head Neck Surg. 2007;133(5):503–10.PubMed
95.
Cho NL, Lin CI, Whang EE, et al. Sulindac reverses aberrant expression and localization of beta-catenin in papillary thyroid cancer cells with the BRAFV600E mutation. Thyroid. 2010;20(6):615–22.PubMed
96.
Rasmussen KD, Helin K. Role of TET enzymes in DNA methylation, development, and cancer. Genes Dev. 2016;30(7):733–50.PubMedPubMedCentral
97.
Breiling A, Lyko F. Epigenetic regulatory functions of DNA modifications: 5-methylcytosine and beyond. Epigenetics Chromatin. 2015;8:24.PubMedPubMedCentral
98.
Szulwach KE, Li X, Li Y, et al. Integrating 5-hydroxymethylcytosine into the epigenomic landscape of human embryonic stem cells. PLoS Genet. 2011;7(6):e1002154.PubMedPubMedCentral
99.
Ribeiro FR, Meireles AM, Rocha AS, et al. Conventional and molecular cytogenetics of human non-medullary thyroid carcinoma: characterization of eight cell line models and review of the literature on clinical samples. BMC Cancer. 2008;8:371.PubMedPubMedCentral
100.
Iancu IV, Botezatu A, Plesa A, et al. Alterations of regulatory factors and DNA methylation pattern in thyroid cancer. Cancer Biomark. 2020;28(2):255–68.PubMed
101.
Noreen F, Kung T, Tornillo L, et al. DNA methylation instability by BRAF-mediated TET silencing and lifestyle-exposure divides colon cancer pathways. Clin Epigenetics. 2019;11(1):196.PubMedPubMedCentral
102.
Sun D, Sun W, Zhou R, Dong A, Zhang H. Relationship between DAPK methylation and gene inactivation in papillary thyroid carcinoma. Eur J Inflamm. 2018;16:1–6.
103.
Zhang K, Li C, Liu J, et al. DNA methylation alterations as therapeutic prospects in thyroid cancer. J Endocrinol Invest. 2019;42(4):363–70.PubMed
104.
Chi P, Allis CD, Wang GG. Covalent histone modifications–miswritten, misinterpreted and mis-erased in human cancers. Nat Rev Cancer. 2010;10(7):457–69.PubMedPubMedCentral
105.
Campbell MJ, Turner BM. Altered histone modifications in cancer. Adv Exp Med Biol. 2013;754:81–107.PubMed
106.
House NC, Koch MR, Freudenreich CH. Chromatin modifications and DNA repair: beyond double-strand breaks. Front Genet. 2014;5:296.PubMedPubMedCentral
107.
Sawan C, Herceg Z. Histone modifications and cancer. Adv Genet. 2010;70:57–85.PubMed
108.
Chen Z, Wang L, Wang Q, et al. Histone modifications and chromatin organization in prostate cancer. Epigenomics. 2010;2(4):551–60.PubMed
109.
Kondo T, Nakazawa T, Ma D, et al. Epigenetic silencing of TTF-1/NKX2-1 through DNA hypermethylation and histone H3 modulation in thyroid carcinomas. Lab Invest. 2009;89(7):791–9.PubMed
110.
Fu H, Cheng L, Sa R, et al. Combined tazemetostat and MAPKi enhances differentiation of papillary thyroid cancer cells harbouring BRAF(V600E) by synergistically decreasing global trimethylation of H3K27. J Cell Mol Med. 2020;24(6):3336–45.PubMedPubMedCentral
111.
Brest P, Lassalle S, Hofman V, et al. MiR-129-5p is required for histone deacetylase inhibitor-induced cell death in thyroid cancer cells. Endocr Relat Cancer. 2011;18(6):711–9.PubMed
112.
Zhang Z, Liu D, Murugan AK, et al. Histone deacetylation of NIS promoter underlies BRAF V600E-promoted NIS silencing in thyroid cancer. Endocr Relat Cancer. 2014;21(2):161–73.PubMedPubMedCentral
113.
Bolden JE, Peart MJ, Johnstone RW. Anticancer activities of histone deacetylase inhibitors. Nat Rev Drug Discov. 2006;5(9):769–84.PubMed
114.
Noguchi H, Yamashita H, Murakami T, et al. Successful treatment of anaplastic thyroid carcinoma with a combination of oral valproic acid, chemotherapy, radiation and surgery. Endocr J. 2009;56(2):245–9.PubMed
115.
Xiao X, Ning L, Chen H. Notch1 mediates growth suppression of papillary and follicular thyroid cancer cells by histone deacetylase inhibitors. Mol Cancer Ther. 2009;8(2):350–6.PubMedPubMedCentral
116.
Zhang L, Xiong D, Liu Q, et al. Genome-wide histone H3K27 acetylation profiling identified genes correlated with prognosis in papillary thyroid carcinoma. Front Cell Dev Biol. 2021;9:682561.PubMedPubMedCentral
117.
Hegedűs L, Rittler D, Garay T, Stockhammer P, Kovács I, Döme B, Theurer S, Hager T, Herold T, Kalbourtzis S, Bankfalvi A, Schmid K, Führer D, Aigner C, Hegedűs B. HDAC inhibition induces PD-L1 expression in a novel anaplastic thyroid cancer cell line. Pathol Oncol Res POR. 2020;26(4):2523–35.PubMed
118.
Liao T, Wang YJ, Hu JQ, et al. Histone methyltransferase KMT5A gene modulates oncogenesis and lipid metabolism of papillary thyroid cancer in vitro. Oncol Rep. 2018;39(5):2185–92.PubMed
119.
Yang X, Liu M, Li M, et al. Epigenetic modulations of noncoding RNA: a novel dimension of cancer biology. Mol Cancer. 2020;19(1):64.PubMedPubMedCentral
120.
Wang T, Li J, Yang L, et al. The role of long non-coding rnas in human imprinting disorders: prospective therapeutic targets. Front Cell Dev Biol. 2021;9:730014.PubMedPubMedCentral
121.
Pajares MJ, Alemany-Cosme E, Goni S, et al. Epigenetic regulation of microRNAs in cancer: shortening the distance from bench to bedside. Int J Mol Sci. 2021;22(14):7350.PubMedPubMedCentral
122.
Chen C, Guo Y, Guo Y, et al. m6A modification in non-coding RNA: the role in cancer drug resistance. Front Oncol. 2021;11:746789.PubMedPubMedCentral
123.
Li X, Abdel-Mageed AB, Mondal D, et al. MicroRNA expression profiles in differentiated thyroid cancer, a review. Int J Clin Exp Med. 2013;6(1):74–80.PubMed
124.
Liao T, Qu N, Shi RL, et al. BRAF-activated LncRNA functions as a tumor suppressor in papillary thyroid cancer. Oncotarget. 2017;8(1):238–47.PubMed
125.
Zheng H, Wang M, Jiang L, et al. BRAF-activated long noncoding RNA modulates papillary thyroid carcinoma cell proliferation through regulating thyroid stimulating hormone receptor. Cancer Res Treat. 2016;48(2):698–707.PubMed
126.
Luzon-Toro B, Fernandez RM, Martos-Martinez JM, et al. LncRNA LUCAT1 as a novel prognostic biomarker for patients with papillary thyroid cancer. Sci Rep. 2019;9(1):14374.PubMedPubMedCentral
127.
Feng K, Liu Y, Xu LJ, et al. Long noncoding RNA PVT1 enhances the viability and invasion of papillary thyroid carcinoma cells by functioning as ceRNA of microRNA-30a through mediating expression of insulin like growth factor 1 receptor. Biomed Pharmacother. 2018;104:686–98.PubMed
128.
Muller K, Fuhrer D, Mittag J, et al. TSH compensates thyroid-specific IGF-I receptor knockout and causes papillary thyroid hyperplasia. Mol Endocrinol. 2011;25(11):1867–79.PubMedPubMedCentral
129.
Panebianco F, Kelly LM, Liu P, et al. THADA fusion is a mechanism of IGF2BP3 activation and IGF1R signaling in thyroid cancer. Proc Natl Acad Sci U S A. 2017;114(9):2307–12.PubMedPubMedCentral
130.
131.
Xu Y, Han YF, Ye B, et al. miR-27b-3p is involved in doxorubicin resistance of human anaplastic thyroid cancer cells via targeting peroxisome proliferator-activated receptor gamma. Basic Clin Pharmacol Toxicol. 2018;123(6):670–7.PubMed
132.
Huang C, Cai Z, Huang M, et al. miR-219-5p modulates cell growth of papillary thyroid carcinoma by targeting estrogen receptor alpha. J Clin Endocrinol Metab. 2015;100(2):E204–13.PubMed
Metadata
Title
Epigenetic modification and BRAF gene mutation in thyroid carcinoma
Authors
Guo Huang
Juan Chen
Jun Zhou
Shuai Xiao
Weihong Zeng
Jiliang Xia
Xi Zeng
Publication date
01-12-2021
Publisher
BioMed Central
Published in
Cancer Cell International / Issue 1/2021
Electronic ISSN: 1475-2867
DOI
https://doi.org/10.1186/s12935-021-02405-w

Other articles of this Issue 1/2021

Cancer Cell International 1/2021 Go to the issue

Primary research

ALDOA inhibits cell cycle arrest induced by DNA damage via the ATM-PLK1 pathway in pancreatic cancer cells

Primary research

Vγ9Vδ2 T cells strengthen cisplatin inhibition activity against breast cancer MDA-MB-231 cells by disrupting mitochondrial function and cell ultrastructure

Review

The significance of exosomal RNAs in the development, diagnosis, and treatment of pancreatic cancer

Primary research

miR-636 inhibits EMT, cell proliferation and cell cycle of ovarian cancer by directly targeting transcription factor Gli2 involved in Hedgehog pathway

Review

Genistein as a regulator of signaling pathways and microRNAs in different types of cancers

Correction

Correction to: Silenced lncRNA DDX11-AS1 or up-regulated microRNA-34a-3p inhibits malignant phenotypes of hepatocellular carcinoma cells via suppression of TRAF5
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits